Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

The 2010 CONNECT MIP Awards recognize the emerging technologies and cutting-edge products that drive San Diego's innovation economy. SUMAVEL DosePro received top honors as the most innovative product for 2010 in the Life Sciences – Medical Products category.

SUMAVEL DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for patients suffering from migraine attacks, and has demonstrated consistent monthly growth in total prescriptions since its U.S. commercial launch in January 2010.  It is the first drug product approved by the U.S. Food and Drug Administration (FDA) which allows for the needle-free, subcutaneous delivery of medication.

Roger L. Hawley, Chief Executive Officer and Director of Zogenix, said, "We are honored that CONNECT has recognized SUMAVEL DosePro, and by extension our proprietary DosePro delivery system, as a significant innovation. San Diego is a rich source of new and exciting technologies, and we are proud to be distinguished in the region as the most innovative medical product within the life sciences category."

SUMAVEL DosePro is currently approved in the United States and Denmark for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache. SUMAVEL DosePro may offer a fast-acting and efficacious treatment alternative to oral and nasal triptans with simple, convenient administration when compared to traditional, needle-based sumatriptan injection. These unique attributes may be ideally suited for challenging migraine attacks, such as morning migraines, fast onset migraine and migraines with vomiting.

Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010. Zogenix has a partnership with Desitin Arzneimittel GmbH to develop and commercialize SUMAVEL DosePro in the European Union.  Desitin plans to launch SUMAVEL DosePro in Denmark in early 2011.

SOURCE Zogenix, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Researchers discover a peptide involved in both migraine and opioid-overuse pain